Clinical Trial Update: Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial of Vactosertib in combination with Pembrolizumab for PD-L1 positive non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Vactosertib (Vactosertib)

Snippet

Sponsor: MedPacto, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED